---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000049"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:36:37.957310+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M

## Summary
- Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.
- BRUKINSA U.S. sales grew 153% and Europe 243% YoY; fifth FDA approval gives broadest BTKi label.
- GAAP operating loss narrowed to $261M from $371M; adjusted operating loss $147M vs $276M.
- TEVIMBRA now approved in U.S. and Europe; advancing late-stage pipeline including sonrotoclax and BTK CDAC.
- Company says progressing toward sustainable profitability with improved operating leverage.

## SEC filing metadata
- accession: 0001651308-24-000049
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/0001651308-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/bgne-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000049
- JSON: https://secwatch.observer/filing/0001651308-24-000049.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000049.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported the three months ended March 31, 2024 results: revenue $752 million.
  - Period: the three months ended March 31, 2024
  - Revenue: $752 million
  - Result: reported results
  source text: as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Reports First Quarter 2024 Financial Results and Business Updates • Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period • BRUKINSA revenue of $489 million, driven by growth in the U.S. and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/0001651308-24-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.